New Drug’s Launch raised Ascendis Pharma A/s (ASND) in the first quarter

Craft partnersAn investment management company published its investor letter “Artisan Mid Cap Fund”. A copy of the letter may be downloaded here. In the first quarter, the Fund of Investors of the Artmx Fund returned -7.40%, the APDMX advisory class fund recorded a return of -7.37%and the APHMX institutional class fund returned 7.35%, compared to -7.12%return for the growth rate of Russell Midcap. North -American shares gained solid Q4 benefits, concluding a strong year. After a period of strong performance of growth actions in 2023 and 2024, value actions obtained leadership in the first quarter of 2025. In an inverse environment, investors moved to actions of smaller volumes, especially in the sectors of public and consumer services, along with those with the highest dividend returns. In addition, see the five main holdings of the fund to find out their best options by 2025.

In his letter of investors of the first quarter of 2025, the Fund Artisan Mid Cap emphasized actions such as Ascendis Pharma a/s (NASDAQ:As body)). Ascendis Pharma a/s (NASDAQ: ASND) is a biopharmaceutical company. The return of one month of Ascendis Pharma A/s (NASDAQ: ASND) was 21.84%, and their shares obtained 27.42% of their value during the last 52 weeks. On May 5, 2025, Ascendis actions Pharma A/s (NASDAQ: ASND) closed to $ 170.74 per action with a market capitalization of $ 10,308 million.

Artisan Mid Cap Fund declared the next one with regard to Ascendis Pharma A/s (NASDAQ: ASND) in his investment letter from the first quarter of 2025:

“Among our best collaborators in the first quarter was Spotify, Rise to pharma a / s (Nasdaq: ASND) and Autozone. The actions of Ascendis experienced strongly in the quarter due to the launch of their last drug, Yorvipath. The drug deals with hippoparathyroidism: a rare endocrine disorder with limited effective treatments. Our opinion is that this will be a significant benefits cycle driver, given the large airship market and the needs not met in the current care. Yorvipath was approved and launched in December and the last results of the company’s earnings showed that the launch is far ahead of expectations. Although it is still early, the initial recipe data admit our upward vision of sales that could exceed the expectations of the market by a wide range. Ascendis, meanwhile, has a third promising drug, CNP (to treat Achondroplasia), which was presented for FDA approval in the first quarter and could be launched by 2026. “

A foreground view of a hand that manipulates a syringe while delivering CNP in a tumor.

Ascendis Pharma A/s (NASDAQ: ASND) is not on our list of 30 most popular actions between coverage funds. According to our database, 45 coverage backgrounds celebrated Ascendis Pharma a/s (NASDAQ: ASND) at the end of the fourth quarter, against 43 of the third trimester. Although we recognize the potential of Ascendis Pharma a/s (NASDAQ: ASND) as an investment, our conviction lies in the belief that the AI ​​actions have a greater promise to obtain higher yields and make it shorter. If you are looking for an IA stock as promising as Nvidia, but you quoted less than five times, see our report on the Ia stock cheap.